Dynamic analysis of a motor-integrated method for a higher milling stability

The productivity in High Speed Cutting is often limited by undesirable vibration effects in the main spindle (chatter). In many cases these limits are far below the technically possible cutting parameters provided by the machine technology. This paper presents a new approach to a motor-integrated milling spindle with an embedded electromagnetic actuator to actively reduce chatter vibrations and increase productivity. It is based on the non-contact application of highly-dynamic damping forces on the spindle shaft. That way the process stability can be increased significantly. By measurement and simulation-based analysis of spindle dynamics and transient and analytical approaches to process stability, the efficiency of the damping method is demonstrated in theory. Finally, a new, soft magnetic composite based motor-integrated electromagnetic actuator is introduced in this article.     

The short of it: Abbreviating the temporal discounting procedure.

A typical temporal discounting procedure determines the present, subjective value (indifference point) of a delayed outcome at 5 to 8 different delays to that outcome. These indifference points are used to determine a single index of discounting called a discounting rate. One concern that remains in the collection of this data is the high number of trials or choices, resulting in participant fatigue or other factors that may affect the validity of the data. In this report, we propose an abbreviated alternative to the more comprehensive and time-consuming discounting procedure. Specifically, we propose that fewer indifference points can be used to determine statistically equivalent discount rates with no loss in data sensitivity. We reanalyzed temporal discounting data obtained with 7 indifference points, and estimated discount rates from all combinations of 2, 3, and 4 of the 7 indifference points. Results indicate that valid and sensitive discounting indices can be obtained with fewer indifference points, and the most appropriate sets of indifference points are highlighted. The proposed abbreviated procedure is likely to be particularly useful when time constraints or participant fatigue is a concern as well as in repeated-measures contexts. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Novel models of intertemporal valuation: Past and future outcomes.

Temporal discounting refers to the reduction in the present subjective value of an outcome as a function of the temporal distance to that outcome. Though a number of mathematical models have been proposed to describe this time/value relationship, this search has largely excluded insights from the literature on memory decay. This study examines the utility of memory decay models by comparing the fits of 4 of these models to fits from established temporal discounting models using past and future temporal discounting data. These results (a) suggest that a single model describes valuation of both future and past outcomes; (b) indicate the exponential-power model, from memory decay literature, is statistically superior in fitting discounting data from both past and future outcomes; and (c) support the advancing perspective of the psychological interconnectedness of the future and past. (PsycINFO Database Record (c) 2010 APA, all rights reserved)     

Angular-scattering characteristics of ferroelectric liquid-crystal electro-optical devices operating in the transient-scattering and the extended-scattering modes

The angular distribution of forward-scattered light in transient-scattering-mode (TSM) and extended-scattering-mode (ESM) ferroelectric liquid-crystal (FLC) devices was evaluated by use of circularly polarized incident light. For both modes the intensity and the distribution of forward-scattered light depended primarily on the FLC birefringence, spontaneous polarization, and the cell path length. In the FLC materials examined, the forward-scattering intensity under ESM drive conditions increased with longer FLC pitch lengths, whereas under TSM conditions stronger forward scattering was observed with increasing FLC spontaneous polarization. Although both TSM and ESM drive conditions displayed a similar angular distribution for forward-scattered light, the intensity of ESM scattering over a 0 degrees -6 degrees range was considerably smaller than that observed in earlier experiments with linearly polarized incident light.     

Preparation and in vitro characterization of gentamycin-impregnated biodegradable beads suitable for treatment of osteomyelitis

A new method for preparing poly(L-lactide) (PLA) biodegradable beads impregnated with an ionic aminoglycoside, gentamycin, is described. The process employs hydrophobic ion pairing to solubilize gentamycin in a solvent compatible with PLA, followed by precipitation with a compressed antisolvent (supercritical carbon dioxide). The resulting precipitate is a homogeneous dispersion of the ion-paired drug in PLA microspheres. The microspheres are approximately 1 microm in diameter and can be compressed into beads (3-6 mm in diameter) strung on surgical sutures for implantation. The bead strings exhibit no significant change in release kinetics upon sterilization with a hydrogen peroxide plasma (Ster-Rad). The kinetics of gentamycin release from the PLA beads are consistent with a matrix-controlled diffusion mechanism. While nonbiodegradable poly(methyl methacrylate) (PMMA) beads initially release gentamycin in a similar manner, the drug release from PMMA ceases after 8 or 9 weeks, while the PLA beads continue to release drug for over 4 months. Moreover, only 10% of the gentamycin is released from the PMMA beads, while PLA beads release more than 60% of their load, if serum is present in the release medium. The PLA system displays improved release kinetics relative to PMMA, is biodegradable, is unaltered by gas sterilization, can be used for a range of antibiotics, and can be manipulated without disintegration. These are all desirable properties for an implantable drug delivery system for the prevention or treatment of osteomyelitis.     

Ventricular myxoma presenting as acute visual loss

We report a case of left ventricular myxoma with embolization to the left posterior cerebral artery, causing acute visual loss. The tumor was successfully resected and a follow-up echocardiography after 21 months revealed no evidence of tumor recurrence. The patient also had a past history of testicular seminoma. We believe that this is the first case report of an association of cardiac myxoma and testicular seminoma.     

GDP-fucose synthetase from Escherichia coli: structure of a unique member of the short-chain dehydrogenase/reductase family that catalyzes two distinct reactions at the same active site

BACKGROUND:. In all species examined, GDP-fucose is synthesized from GDP-mannose in a three-step reaction catalyzed by two enzymes, GDP-mannose 4,6 dehydratase and a dual function 3, 5-epimerase-4-reductase named GDP-fucose synthetase. In this latter aspect fucose biosynthesis differs from that of other deoxy and dideoxy sugars, in which the epimerase and reductase activities are present as separate enzymes. Defects in GDP-fucose biosynthesis have been shown to affect nodulation in bacteria, stem development in plants, and are associated with the immune defect leukocyte adhesion deficiency type II in humans. RESULTS:. We have determined the structure of GDP-fucose synthetase from Escherichia coli at 2.2 A resolution. The structure of GDP-fucose synthetase is closely related to that of UDP-galactose 4-epimerase and more distantly to other members of the short-chain dehydrogenase/reductase family. We have also determined the structures of the binary complexes of GDP-fucose synthetase with its substrate NADPH and its product NADP+. The nicotinamide cofactors bind in the syn and anti conformations, respectively. CONCLUSIONS:. GDP-fucose synthetase binds its substrate, NADPH, in the proper orientation (syn) for transferring the 4-pro-S hydride of the nicotinamide. We have observed a single binding site in GDP-fucose synthetase for the second substrate, GDP-4-keto,6-deoxy-mannose. This implies that both the epimerization and reduction reactions occur at the same site in the enzyme. As is the case for all members of the short-chain family of dehydrogenase/reductases, GDP-fucose synthetase retains the Ser-Tyr-Lys catalytic triad. We propose that this catalytic triad functions in a mechanistically equivalent manner in both the epimerization and reduction reactions. Additionally, the X-ray structure has allowed us to identify other residues that are potentially required for substrate binding and catalysis.     

Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion

The renal uptake of radiolabeled antibody fragments and peptides presents a problem in radioimmunodetection and therapy, compromising lesion sensitivity, especially with intracellularly-retained isotopes. Previously, we showed that cationic amino acids and their derivatives are capable of significantly reducing kidney uptake in animals. We report our initial clinical results of successful renal uptake reduction in five patients who underwent cancer radioimmunodetection with 99mTc-anti-CEA Fab' fragments. METHODS: The patients were infused with two liters of a commercially-available nutritive amino acid solution (containing approximately 2.25 g/liter lysine-glutamate and 2.50 g/liter arginine), whereas 75 control patients received the same volume of saline (quantification of organ and tumor kinetics from conjugate whole-body views by ROI technique). RESULTS: The renal uptake in the amino acid group was significantly lower (p<0.05) than in the control group (11.1 +/- 2.0% injected dose versus 17.7 +/- 7.0% injected dose at 24 hr postinjection), whereas the uptake of all other organs remained unaffected. Gel filtration chromatography of the urine taken from amino-acid-treated patients showed that a significantly higher amount of excreted activity was bound to intact Fab' (53% of excreted activity) in contrast to only less than 10% in the control group. CONCLUSION: The renal uptake of monoclonal antibody fragments in patients can be reduced significantly by amino acid infusion, even at considerably lower doses than those that were safe and effective in animals. As was found in animals, the mechanism seems to rely on an inhibition of the re-absorption of tubularly-filtered proteins by the proximal tubule cells. These results encourage further clinical trials to lower the renal uptake experienced in radioimmunodetection, as well as in therapeutic trials with antibody fragments and peptides.     

Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family

Recent data suggesting complex I dysfunction in Parkinson's disease (PD) arises from mitochondrial DNA (mtDNA) mutation does not conclusively answer whether the responsible genetic lesion is inherited (primary) or somatic (secondary). To address this question, we identified a family in which multiple members over three generations are affected with PD through exclusively maternal lines. Cytoplasmic hybrids (cybrids) were created for 15 family members over two generations by transferring each individual's mtDNA to mtDNA-depleted human neuroblastoma cells. Eight of the 15 cybrid lines contained mtDNA obtained from maternally descended family members and seven contained mtDNA from paternally descended family members. After 6 weeks of culture, cybrid cell lines were assayed for complex I activity and oxidative stress, and mitochondrial morphology was analyzed by electron microscopy. Compared with the cybrid lines containing mtDNA from paternal descendants, cybrid lines containing mtDNA from maternal descendants had lower complex I activity, increased reactive oxygen species production, increased radical scavenging enzyme activities, and more abnormal mitochondrial morphologic features. These findings were present in cybrid lines containing mtDNA from maternal descendants with PD as well as in currently asymptomatic young maternal descendants, and support a precedent for inherited mtDNA mutation in some persons with PD.